Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Surgically Accessible Glioblastoma
NCT04606316Phase 1Active, not recruiting
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nivolumab and ipilimumab in glioblastoma (GBM) (3 arms). Primary endpoints: Tumor Infiltrating T Lymphocyte Density at 24 months and Safety of Study Drug Therapy at 24 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04606316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606316.